Skip to main content
SpringerLink
Log in

Regadenoson: A focused update

  • Review Article
  • Published:
Journal of Nuclear Cardiology Aims and scope

Abstract

Since its approval by the Food and Drug Administration in 2008, regadenoson has become the most commonly used vasodilator in the United States. Previous reviews have summarized the pre-clinical and clinical data on the use of regadenoson for myocardial perfusion imaging (MPI). Since then, data have emerged on the safety of this agent in special groups of patients such as those with chronic kidney disease, airway disease (asthma and chronic obstructive pulmonary disease), and liver disease. There has also been recent interest in the use of regadenoson in hybrid protocols with exercise as a way to improve patient tolerance and image quality. Finally, although regadenoson was approved for clinical use based on the agreement rate of regadenoson MPI and adenosine MPI with regards to perfusion abnormalities, data are now available on the prognostic data derived from regadenoson MPI. We will briefly summarize these recent reports here in a focused update on the use of regadenoson for MPI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  1. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trials. J Nucl Cardiol 2007;14:645-58.

    Article  PubMed  Google Scholar 

  2. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, on behalf of the ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. J Am Coll Cardiol Imaging 2008;1:307-16.

    Article  Google Scholar 

  3. Al Jaroudi W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.

    Article  PubMed  CAS  Google Scholar 

  4. Zoghbi GJ, Iskandrian AE. Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol 2012;19:126-41.

    Article  PubMed  Google Scholar 

  5. Iskandrian AE, Garcia EV, editors. Nuclear cardiac imaging: Principles and applications. 4th ed. Oxford: Oxford University Press; 2008.

    Google Scholar 

  6. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the advance MPI 2 trial. J Am Coll Cardiol Imaging 2009;2:959-68.

    Article  Google Scholar 

  7. Sherwood M, Hage FG, Heo J, Shaw LJ, Cerqueira MD, Iskandrian AE. SPECT myocardial perfusion imaging as an endpoint. J Nucl Cardiol 2012;19:891-4.

    Article  PubMed  Google Scholar 

  8. Iskandrian AE, Garcia EV, Faber T, Mahmarian JJ. Automated assessment of serial SPECT myocardial perfusion images. J Nucl Cardiol 2009;16:6-9.

    Article  PubMed  Google Scholar 

  9. AlJaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol 2010;105:133-5.

    Article  PubMed  CAS  Google Scholar 

  10. Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 2012;19:319-29.

    Article  PubMed  Google Scholar 

  11. AlJaroudi W, Iqbal F, Koneru J, Bhambhvani P, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage liver disease. J Nucl Cardiol 2011;18:90-5.

    Article  PubMed  Google Scholar 

  12. Zoghbi GJ, Patel AD, Ershadi RE, Heo J, Bynon JS, Iskandrian AE. Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation. Am J Cardiol 2003;92:1066-71.

    Article  PubMed  Google Scholar 

  13. Leaker BR, O’Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo controlled trial. J Nucl Cardiol 2008;15:329-36.

    Article  PubMed  Google Scholar 

  14. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milken D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319-28.

    Article  PubMed  Google Scholar 

  15. Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681-92.

    Article  PubMed  Google Scholar 

  16. Thompson RC. Regadenoson stress in patients with asthma and COPD: A breath of fresh air. J Nucl Cardiol 2012;19:647-8.

    Article  PubMed  Google Scholar 

  17. Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milken D, et al. The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective a (2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.

    Article  PubMed  Google Scholar 

  18. Kwon DH, Cerqueira MD, Young R, Houghtaling P, Lieber E, Menon V, et al. Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: Initial clinical experience in 1263 patients. J Nucl Cardiol 2010;17:853-7.

    Article  PubMed  Google Scholar 

  19. Partington S, Lanka V, Hainer J, Blankstein R, Skali H, Forman D, et al. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test. J Nucl Cardiol 2012;19:970-8.

    Article  PubMed  Google Scholar 

  20. Thompson RC, Patil H, Thompson EC, Thomas GS, Al-Amoodi M, Kennedy KF, et al. Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise. J Nucl Cardiol 2012. doi:10.1007/s12350-012-9660-4.

  21. Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J, et al. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. J Am Coll Cardiol Imaging 2012;10:1014-21.

    Article  Google Scholar 

  22. Hage FG, Dean P, Bhatia V, Iqbal F, Heo J, Iskandrian AE. The prognostic value of the heart rate response to adenosine in relation to diabetes mellitus and chronic kidney disease. Am Heart J 2011;162:356-62.

    Article  PubMed  CAS  Google Scholar 

  23. Hage FG, Dean P, Iqbal F, Heo J, Iskandrian AE. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2011;18:1086-94.

    Article  PubMed  Google Scholar 

  24. Iqbal FM, AlJaroudi W, Sanam K, Mallela R, Heo J, Iskandrian AE, et al. Reclassification of cardiovascular risk in patients with normal myocardial perfusion imaging using heart rate response to vasodilator stress. Am J Cardiol 2012. doi:10.1016/j.amjcard.2012.09.013.

Download references

Conflict of interest

Dr Iskandrian is on the advisory panel of Astellas Pharma. Drs Hage and Iskandrian report investigator-initiated grant support from Astellas Pharma. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Author information

Authors and Affiliations

  1. Division of Cardiovascular Diseases, University of Alabama at Birmingham, 318 LHRH, 1900, University Blvd, Birmingham, AL, 35294, USA

    Gopal Ghimire MD, Fadi G. Hage MD, FACC, Jaekyeong Heo MD, FACC & Ami E. Iskandrian MD, MACC

  2. Section of Cardiology, Birmingham Veteran’s Administration Medical Center, Birmingham, AL, USA

    Fadi G. Hage MD, FACC

Authors
  1. Gopal Ghimire MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fadi G. Hage MD, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaekyeong Heo MD, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ami E. Iskandrian MD, MACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fadi G. Hage MD, FACC.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghimire, G., Hage, F.G., Heo, J. et al. Regadenoson: A focused update. J. Nucl. Cardiol. 20, 284–288 (2013). https://doi.org/10.1007/s12350-012-9661-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12350-012-9661-3

Keywords

Search

Navigation